Adam Feuerstein said in the following article "Amarin has decided to block wholesaler prescription data from third-party data services IMS Health and Wolters Kluwer. This makes it difficult, if not impossible, for analysts and institutional investors to measure weekly and monthly Vascepa prescriptions."
This is a total lie. Adam once again has jumped to conclusions without facts and he has not corrected himself. Amrn has not blocked any wholesale prescription data. He he is trying to come across like AMRN is trying to hide something...lol...Good one Adam... When you found out you were wrong why not correct the article? Perhaps because you just lied. Who would correct a lie?
I would think the prescription data would leak out given the number of people that do have access to it.
As for you AF haters. Are you aware you have fallen into Adams trap? . Clicking on his articles pays his salary. Ignore him.
Have no idea if what Adam F said regarding AMRN blocking any wholesale prescription data is true or false. Do you have any facts one way or the other, or are you just upset because he made that statement?
If AMRN did block that data it really wouldn't be that strange frankly. Companies with new drugs or products often block early sales data to the public, and their competition. What benefit to AMRN would there be in disclosing such early data? I see only negatives frankly. If early sales are slow, why telegraph that to the competition? If they are big why let the competition know that either so the competition can discount their product further and undercut AMRN on price?
I agree it makes sense for AMRN to block scripts. It could potentially make for wild stock fluctuations.
What we do know - We know Canaccord was able to see the scripts within a day or two of when Adam stated they were not available. Canaccord included a comment about them in their research note. Adam first pasted something in from IMS that said a wholesaler had blocked scripts. Now he is saying that there is a customer service bulletin saying that Amarin is blocking scripts. He has not shown that to anyone that I am aware of. No other analyst has made this same comment.
We can all hate AF but we continue to read him, and for good reason...
He called the outright collapse and failed trail for CLSN while everyone else was calling it the next Genentech. He even stated the scientific reasons why their trial would fail, which ended up being almost 100% right on as well.
So we can continue to hate the guy but we still read him don't we? LOL
golongin2008 I think you meant to say Steve Rosenmen called it 2 weeks before and gave good reasons why it would fail. If anything AF copied him or someone else he is a worm and after reading your post I now know why you like him.
Sentiment: Strong Buy
Golong, for every clsn that AF gets right there is a kerx that AF gets wrong. I do read AF but not for his opinion(s) which is no better than 50-50. I read him for his facts reporting. Basically I am claiming that I can tell when he is reporting facts (which if important enough I will check for myself) and I will ignore him when he offers his opinions which more often than not originate from his derriere.
I only read what he puts out on AMRN...This is the 4th time he has put out false information regarding AMRN. I am here to call him out every time he does.
"Amarin has decided to block wholesaler prescription data from third-party data services IMS Health and Wolters Kluwer. This makes it difficult, if not impossible, for analysts and institutional investors to measure weekly and monthly Vascepa prescriptions."